Vaccinia virus (ATCC® VR-2153)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain vTF7-3 [Wr]
Applications
Expresses bacteriophage T[7] RNA polymerase.
Expresses bacteriophage T[7] RNA polymerase.
Biosafety Level 2
Isolation
Constructed in vitro
Product Format frozen
Storage Conditions -70°C
Comments
Cells which have been infected with this construct can be transfected by plasmids which contain a gene targeted for expression inserted between a T7 promoter and T7 terminator.
Expresses bacteriophage T[7] RNA polymerase.
Recombinant virus constructed in vitro.
Expresses bacteriophage T[7] RNA polymerase.
Expression of the T7 RNA polymerase is directed by the P7.5 promoter which includes early and late regulatory signals.
Constructed by transfecting vaccinia virus-infected cells with pTF703 (ATCC 67202).
Effect on Host
Yes, in vitro effects: Cytopathic effects (plaque formation) on BS-C-1 and CV-1 monolayers
CPE, rounding, stringing, and cell destruction
Effect on Host
Yes, in vitro effects: Cytopathic effects (plaque formation) on BS-C-1 and CV-1 monolayers
CPE, rounding, stringing, and cell destruction
Name of Depositor NIH, B Moss, NIH
Source
Constructed in vitro
References

Fuerst TR, et al. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83: 8122-8126, 1986. PubMed: 3095828

Zheng Z, et al. Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding. J. Virol. 70: 8029-8040, 1996. PubMed: 8892927